夜勤労働者におけるAkkermansia Muciniphilaおよびベルベリン補給のインスリン感受性への影響 (Shift2Health)
Akkermansia Muciniphilaとベルベリン補給が交代勤務者のインスリン感受性に及ぼす影響:Shift2Healthプロジェクト内での二重盲検、無作為化、プラセボ対照、クロスオーバー試験
Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns. These behavioral and physiological disturbances impair glucose metabolism and are further influenced by the gut microbiota. In particular, the bacterium Akkermansia muciniphila has been linked to improved metabolic health, including enhanced insulin sensitivity, lipid regulation, and maintenance of intestinal barrier integrity. Berberine, a bioactive plant-derived compound, has demonstrated metabolic benefits, including upregulation of A. muciniphila, improvement of insulin sensitivity, and modulation of lipid metabolism.
Together, these complementary mechanisms suggest that combined A. muciniphila supplementation and berberine administration may synergistically improve metabolic health in shift workers by targeting gut microbiota composition and circadian-regulated metabolic pathways.
Based on this rationale, a double-blind, randomized, placebo-controlled, crossover study is being conducted in 200 night-shift workers from healthcare and industrial sectors in Austria and Denmark. Participants are stratified by age, sex, and work sector and randomly assigned to intervention sequences. Each participant receives either the combined supplement or placebo for 12 weeks, followed by a four-week washout, after which the alternate intervention is administered for another 12 weeks, with a total participation of 28 weeks.
Assessments are performed at four study visits and include anthropometry, body composition, blood pressure, and collection of blood, urine, and feces. Participants complete validated questionnaires on dietary intake, lifestyle, work schedules, and general health to monitor behavioral patterns throughout the study. Dietary intake is recorded for four days prior to each sampling visit in consideration of shift schedules. Sleep duration and quality are monitored via diaries and actigraphy and aligned with dietary records. Circadian variation is minimized by standardizing sampling times and implementing a fasting and synchronization period prior to visits.
The primary outcome is insulin sensitivity, measured by HOMA-IR. Secondary exploratory outcomes include gut microbiota composition and diversity, biomarkers of intestinal permeability and inflammation, lipid profiles, body composition, sleep quality, and dietary behavior.
These measures collectively provide a comprehensive evaluation of the metabolic, microbiome, and circadian effects of combined A. muciniphila and berberine supplementation in night-shift workers.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Miriam Ressler, PhD
- 電話番号:+4331654536677
- メール:miriam.ressler@fh-joanneum.at
研究場所
-
-
Styria
-
Graz、Styria、オーストリア、8020
- 募集
- FH JOANNEUM University of Applied Sciences
-
コンタクト:
- Miriam Ressler, PhD
- 電話番号:+4331654536677
- メール:miriam.ressler@fh-joanneum.at
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Health care or industrial shift worker
- Employed or self-employed working ≥ 24 h/week
- Current night shift work (night shift defined as a work schedule that includes at least 3 hours of work between 00:00 and 5:00) with at least 2 consecutive nights/month
- Night shift work duration > 3 years
- 4 or more night shifts/month
Exclusion Criteria:
- BMI of 40 kg/m² or higher
- Pregnancy or planned pregnancy within 6 months of enrolment or breastfeeding women
- Bariatric surgery
- Surgery in the 3 months prior to the study or planned surgery in the next 6 months that, in the opinion of the investigators, could potentially affect the outcome of the study
- Diagnosed diabetes type 1 or type 2
- Uncontrolled thyroid disease (confirmed by clinically significant abnormal TSH/T4 levels without stable medication for more than 3 months)
- Chronic diseases (renal failure, active hepatitis, liver cirrhosis, myocardial infarction within the last 2 years, stroke, chronic obstructive pulmonary disease or cancer)
- Immunodeficiency syndrome, active autoimmune or autoinflammatory disease (e.g. multiple sclerosis, lupus, rheumatoid arthritis), inflammatory bowel disease (e.g. IBS or ulcerative colitis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever). Grave's disease, Hashimoto thyroiditis, Celiac disease, sarcoidosis, Lichen planus, are allowed, if well treated and stable
- Regular intake of anticoagulants
- Known allergy to any inactive or active ingredients in the study products
- Participation in other clinical intervention trials during the study
- Current or planned participation in a weight loss program (including intermittent fasting), extreme diet, or vigorous exercise (e.g., running, fast cycling, swimming laps, or playing intense sports that quickly raise your heart rate)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:AB Group
Participants will first receive Verum (A) for 3 months. After a 4-week washout period, they will receive Placebo (B) for 3 months. |
1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day. 1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day. |
|
実験的:BA Group
Participants will first receive Placbo (B) for 3 months. After a 4-week washout period, they will receive Verum (A) for 3 months. |
1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day. 1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change of 3-months supplementation with A. muciniphila and berberine on insulin resistance using HOMA-IR compared to placebo
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Homeostasis Model Assessment of Insulin Resistance, calculated as (fasting insulin (μU/ml) x fasting glucose (mmol/l)) / 22.5, will be assessed to calculate the change between baseline and endpoint in the two periods |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in gut microbiom composition between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Gene sequencing of the 16S rRNA is performed on the stool samples to compare microbiota diversity and relative abundance |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in FABPi between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of FABP intestinal (FABPi) in blood (pg/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in zonulin between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of zonulin in blood (ng/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in LPB between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of lipopolysaccharide-binding protein (LPB) in blood (pg/mL) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in CRP between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Analysis of high-sensitive C-reactive protein (hs-CRP, mg/L) in blood |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in stool short-chain fatty acids (SCFA) between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
SCFA will be extracted and quantitatively analysed by GC-MS (µmol/g) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in blood lipid profile and cardiovascular markers between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Measurement of cholesterol (mmol/L), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density lipoprotein (HDL-C, mmol/L), and triglyceride levels (TG, mmol/L) in blood |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in blood pressure between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Systolic BP (mmHG) and diastolic BP (mmHG) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in melatonin between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
6-sulfatoxymelatonin in urine (µg/L) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in BMI between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Body mass index (BMI) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in body composition between the baseline and endpoint change in the two periods
時間枠:At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
Bioelectrical Impedance Analysis (BIA) |
At the beginning and the end of each intervention period (week 0, 12, 16, 28)
|
|
Change in metabolomics at the end of the two periods
時間枠:At the beginning and the end of each intervention period (week 12, week 28)
|
Metabolomic profiles obtained with LC-MS/MS |
At the beginning and the end of each intervention period (week 12, week 28)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 1306/2025
- 101080788 (その他の助成金/資金番号:Horizon Europe)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。